Взаимосвязь между уровнем ST2 и морфофункциональными изменениями при декомпенсации хронической сердечной недостаточности

Моисеев В.С. Генетика кардиомиопатий // Кардиология.-Москва, 2003.- 3.-С. 85-89

Моисеев В.С., Киякбаев Г.К. Проблема классификации кардиомиопатии. Кардиология 2009; 1:65-70

Pascual-Figal D. A., Januzzi J. L. The biology of ST2: The International ST2 Consensus Panel. Am. J. Cardiol. 2015. 115 (7): 3 B–7 B. DOI: 10.1016/j.amjcard.2015.01.034

Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T. K. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor related protein ST2 and induces T helper type 2-associated cytokines // Immunity. 2005. 23: 479–490. DOI: 10.1016/j.immuni.2005.09.015

Kakkar R., Lee R. T. The IL-33/ST2 pathway: Therapeutic target and novel biomarker // Nat. Rev. Drug Discov. 2008. 7: 827–840. DOI: 10.1038/nrd2660

Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106 (23):2961–6. PMID:12460879 13.

Weir RAP, Miller AM, Murphy GEJ, Clements S, Steedman T, Connell JMC et al. Serum Soluble ST2. Journal of the American College of Cardiology. 2010;55 (3):243–50. DOI:10.1016/j. jacc. 2009.08.047

Maggioni A.P., Dahlström U., Filippatos G. et al. EUR Observational Research Programme: regional differences and 1-year followup results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15 (7):808–817. DOI: 10.1093/eurjhf/hft050

Harjola V.P., Follath F., Nieminen M. S. et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010;12 (3):239–248. DOI: 10.1093/eurjhf/hfq002

Maggioni A., Dahlstrom U., Filippatos G. et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010;12:1076–1084. DOI: 10.1093/eurjhf/hfq154

Krumholz H.M., Merrill A.R., Schone E.M. et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes 2009;5:407–413. DOI: 10.1161/CIRCOUTCOMES.109.883256

Мареев В. Ю., Агеев Ф. Т., Беграмбекова Ю. Л., Васюк Ю. А., Гарганеева А. А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6). Стр. 1-164 https://doi.org/10.18087/cardio.2475

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF / AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62 (16):e147–239. DOI:10.1016 / j. jacc. 2013.05.019.

Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-6. doi:10.1093/ eurheartj/ehm342.

Сережина Е.К., Обрезан А.Г. Биомаркеры повреждения и ремоделирования миокарда в диагностике сердечной недостаточности с сохранной фракцией выброса. РМЖ «Медицинское обозрение» №10(I). стр. 23-26

Dieplinger B, Mueller T. Soluble sT2 in heart failure. Clin Chim Acta. 2015; 443: 57-70. DOI: 10.1016/j.cca.2014.09.021

КапелькоВ.И., ВекслерВ.И., КоповичМ.И. Патофизиологические аспекты кардиомиопатии. Кардиология 1991. 11Ж5-11.

Rehman S.U., Mueller T., Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 2008: 52 (18): 1458–65. doi:10.1016/j.jacc.2008.07.042

J.L. Januzzi Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res. 2013;6(4):493-500 DOI: 10.1007/ s12265-013-9459-y.

Manzano-Fernández S., Mueller T., Pascual-Figal D., Truong Q.A., Januzzi J.L. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107(2):259-67. doi: 10.1016/j.amjcard.2010.09.011.

Dieplinger B., Januzzi J.L., Steinmair M., Gabriel C., Poelz W., Haltmayer M., Mueller T. Analytical and clinical evaluation of a novel highsensitivity assay for measurement of soluble ST2 in human plasma—the Presage ST2 assay. Clin Chim Acta. 2009; 409(1-2):33-40. DOI: 10.1016/j.cca.2009.08.010

Breidthardt T., Balmelli C., Twerenbold R., Mosimann T., Espinola J., Haaf P. et al. Heart Failure Therapy: Induced Early ST2 Changes May Offer Long-Term Therapy Guidance. J Card Fail. 2013;19(12):821-8. DOI: 10.1016/j.cardfail.2013.11.003

Dr Scott D Solomon, Prof Michael Zile, MD Prof Burkert Pieske, Prof Adriaan Voors, Amil Shah, MDElisabeth Kraigher-Krainer, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial DOI: https://doi.org/10.1016/S0140-6736(12)61227-6

Капелько В.И. Внеклеточный матрикс миокарда и его изменения при заболеваниях сердца. Кардиология 2000 №9, стр 78-89.

Weir R.A., Miller A.M., Murphy G.E., Clements S., Steedman T., Connell J.M. et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243-50. DOI: 10.1016/j.jacc.2009.08.047